CytRx con­cedes that its on­ly drug flunked a PhI­II sar­co­ma test, rout­ing shares

Three years af­ter one of its drugs had to be scrapped fol­low­ing a failed study, CytRx was forced to con­cede that its Phase III study of its lead drug al­dox­oru­bicin flopped against treat­ment re­sis­tant soft tis­sue sar­co­mas.

The com­pa­ny tried to put the most pos­i­tive spin on it, say­ing that the re­sults had been con­found­ed by an in­ter­rup­tion due to a tem­po­rary par­tial clin­i­cal hold in 2014. But the pro­gres­sion-free sur­vival rate for the drug came in at 4.17 months, hard­ly dis­tin­guish­able from the 4.04 months tracked for in­ves­ti­ga­tors’ choice among stan­dard treat­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.